Natera, a leading company specializing in cell-free DNA testing, has announced its endorsement of the 2024 Clinical Practice Guideline established by the Kidney Disease Improving Global Outcomes (KDIGO) organization. This guideline promotes the use of genetic testing to identify the root cause of chronic kidney disease (CKD) in the majority of patients, emphasizing the significance of genetic testing in determining the cause of CKD and its impact on clinical management.
The KDIGO guideline specifically outlines various scenarios where genetic testing can provide valuable insights for CKD patients, such as in cases with a high prevalence of monogenic subtypes, early onset of CKD, syndromic features, consanguinity, potential targeted treatments, and instances where kidney biopsy does not yield informative results.
Natera’s RenasightTM test is in alignment with this guideline, offering comprehensive genetic testing for kidney disease. This test screens for hereditary causes of kidney disease, providing essential information for disease management, predicting disease progression, and guiding treatment decisions. With over 380 genes analyzed by genetic experts, the Renasight test offers actionable insights and can be accessed through remote testing services with rapid results turnaround.
A recent study conducted by Natera, known as RenaCARE, showcased the diagnostic and clinical benefits of Renasight in CKD patients. The study revealed that genetic testing with Renasight resulted in new or reclassified diagnoses for half of positive patients, influencing treatment plans for one-third of positive patients. These findings underscore the importance and advantages of genetic testing in effectively managing chronic kidney disease.
NTRA Stock Shows Mixed Performance on March 14, 2024: What to Expect Next
On March 14, 2024, NTRA stock showed some mixed performance as it traded near the top of its 52-week range and above its 200-day simple moving average. Despite these positive indicators, the stock experienced a slight decrease in price, falling $1.20 since the market last closed, representing a 1.35% drop.
Investors may be keeping a close eye on NTRA stock to see if this downward trend continues or if the stock rebounds in the coming days. The fact that the stock is still trading near the top of its 52-week range and above its 200-day moving average suggests that there may still be some positive momentum for NTRA in the long term.
NTRA Stock Shows Positive Performance with 31.99% Increase in Revenue
On March 14, 2024, NTRA stock showed positive performance based on its financial results. According to data from CNN Money, NTRA reported a total revenue of $1.08 billion for the past year, which represents a 31.99% increase compared to the previous year. In the fourth quarter alone, the company generated $311.11 million in total revenue, showing a 15.95% increase from the previous quarter.
In terms of net income, NTRA reported a loss of $434.80 million for the past year, but this figure actually represents a 20.63% improvement compared to the previous year. In the fourth quarter, the company’s net loss was $78.03 million, showing a significant 28.43% increase from the previous quarter.
Earnings per share (EPS) for NTRA also showed positive growth trends. The company reported an EPS of -$3.78 for the past year, which is a 32.08% improvement compared to the previous year. In the fourth quarter, the EPS was -$0.65, which remained flat compared to the previous quarter.
